Compare Summit Therapeutics Inc (SMMT) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tyson Foods, Inc. — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Tyson Foods, Inc. trades at $57.25 (market cap $20.42B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.52% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TSN | |
|---|---|---|
Market Cap | $10.48B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $29.32 | $68.75 |
52-Week Low | $13.05 | $50.72 |
Enterprise Value | $9.90B | $28.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Tyson Foods (TSN) trades at $57.05, down 1.25% with neutral technical indicators. The company shows stable revenue near $54B but thin margins, with a 0.81% net income margin and elevated P/E of 45.67. Recent earnings beat expectations in Q1 2026, while analyst consensus is mixed with a $68.80 price target. Dividend payments continue at $0.51 quarterly.
TSN offers modest growth potential with analyst upside but faces margin pressure and competitive challenges. The stock's valuation appears stretched relative to earnings, while consistent dividends provide income support. Key risks include commodity cost volatility and execution in the competitive protein market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
